131 related articles for article (PubMed ID: 16580212)
1. Novel potent and selective calcium-release-activated calcium (CRAC) channel inhibitors. Part 1: synthesis and inhibitory activity of 5-(1-methyl-3-trifluoromethyl-1H-pyrazol-5-yl)-2-thiophenecarboxamides.
Yonetoku Y; Kubota H; Okamoto Y; Toyoshima A; Funatsu M; Ishikawa J; Takeuchi M; Ohta M; Tsukamoto S
Bioorg Med Chem; 2006 Jul; 14(14):4750-60. PubMed ID: 16580212
[TBL] [Abstract][Full Text] [Related]
2. Novel potent and selective Ca2+ release-activated Ca2+ (CRAC) channel inhibitors. Part 3: synthesis and CRAC channel inhibitory activity of 4'-[(trifluoromethyl)pyrazol-1-yl]carboxanilides.
Yonetoku Y; Kubota H; Miyazaki Y; Okamoto Y; Funatsu M; Yoshimura-Ishikawa N; Ishikawa J; Yoshino T; Takeuchi M; Ohta M
Bioorg Med Chem; 2008 Nov; 16(21):9457-66. PubMed ID: 18835179
[TBL] [Abstract][Full Text] [Related]
3. Novel potent and selective calcium-release-activated calcium (CRAC) channel inhibitors. Part 2: Synthesis and inhibitory activity of aryl-3-trifluoromethylpyrazoles.
Yonetoku Y; Kubota H; Okamoto Y; Ishikawa J; Takeuchi M; Ohta M; Tsukamoto S
Bioorg Med Chem; 2006 Aug; 14(15):5370-83. PubMed ID: 16616503
[TBL] [Abstract][Full Text] [Related]
4. Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives.
Jo MN; Seo HJ; Kim Y; Seo SH; Rhim H; Cho YS; Cha JH; Koh HY; Choo H; Pae AN
Bioorg Med Chem; 2007 Jan; 15(1):365-73. PubMed ID: 17035033
[TBL] [Abstract][Full Text] [Related]
5. Targeting gut T cell Ca2+ release-activated Ca2+ channels inhibits T cell cytokine production and T-box transcription factor T-bet in inflammatory bowel disease.
Di Sabatino A; Rovedatti L; Kaur R; Spencer JP; Brown JT; Morisset VD; Biancheri P; Leakey NA; Wilde JI; Scott L; Corazza GR; Lee K; Sengupta N; Knowles CH; Gunthorpe MJ; McLean PG; MacDonald TT; Kruidenier L
J Immunol; 2009 Sep; 183(5):3454-62. PubMed ID: 19648266
[TBL] [Abstract][Full Text] [Related]
6. Characterization of selective Calcium-Release Activated Calcium channel blockers in mast cells and T-cells from human, rat, mouse and guinea-pig preparations.
Rice LV; Bax HJ; Russell LJ; Barrett VJ; Walton SE; Deakin AM; Thomson SA; Lucas F; Solari R; House D; Begg M
Eur J Pharmacol; 2013 Mar; 704(1-3):49-57. PubMed ID: 23454522
[TBL] [Abstract][Full Text] [Related]
7. Basiliolides, a class of tetracyclic C19 dilactones from Thapsia garganica, release Ca(2+) from the endoplasmic reticulum and regulate the activity of the transcription factors nuclear factor of activated T cells, nuclear factor-kappaB, and activator protein 1 in T lymphocytes.
Navarrete C; Sancho R; Caballero FJ; Pollastro F; Fiebich BL; Sterner O; Appendino G; Muñoz E
J Pharmacol Exp Ther; 2006 Oct; 319(1):422-30. PubMed ID: 16840645
[TBL] [Abstract][Full Text] [Related]
8. Lead discovery and optimization of T-type calcium channel blockers.
Park JH; Choi JK; Lee E; Lee JK; Rhim H; Seo SH; Kim Y; Doddareddy MR; Pae AN; Kang J; Roh EJ
Bioorg Med Chem; 2007 Feb; 15(3):1409-19. PubMed ID: 17150365
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and SAR studies of a novel series of T-type calcium channel blockers.
Park SJ; Park SJ; Lee MJ; Rhim H; Kim Y; Lee JH; Chung BY; Lee JY
Bioorg Med Chem; 2006 May; 14(10):3502-11. PubMed ID: 16434203
[TBL] [Abstract][Full Text] [Related]
10. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship study and discovery of indazole 3-carboxamides as calcium-release activated calcium channel blockers.
Bai S; Nagai M; Koerner SK; Veves A; Sun L
Bioorg Med Chem Lett; 2017 Feb; 27(3):393-397. PubMed ID: 28057422
[TBL] [Abstract][Full Text] [Related]
12. Syntheses, calcium channel agonist-antagonist modulation activities, and nitric oxide release studies of nitrooxyalkyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2,1,3-benzoxadiazol-4-yl)pyridine-5-carboxylate racemates, enantiomers, and diastereomers.
Shan R; Velazquez C; Knaus EE
J Med Chem; 2004 Jan; 47(1):254-61. PubMed ID: 14695839
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of 4-piperidinecarboxylate and 4-piperidinecyanide derivatives for T-type calcium channel blockers.
Woo HM; Lee YS; Roh EJ; Seo SH; Song CM; Chung HJ; Pae AN; Shin KJ
Bioorg Med Chem Lett; 2011 Oct; 21(19):5910-5. PubMed ID: 21843937
[TBL] [Abstract][Full Text] [Related]
14. YM-58483, a selective CRAC channel inhibitor, prevents antigen-induced airway eosinophilia and late phase asthmatic responses via Th2 cytokine inhibition in animal models.
Yoshino T; Ishikawa J; Ohga K; Morokata T; Takezawa R; Morio H; Okada Y; Honda K; Yamada T
Eur J Pharmacol; 2007 Apr; 560(2-3):225-33. PubMed ID: 17307161
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.
Yang ZQ; Barrow JC; Shipe WD; Schlegel KA; Shu Y; Yang FV; Lindsley CW; Rittle KE; Bock MG; Hartman GD; Uebele VN; Nuss CE; Fox SV; Kraus RL; Doran SM; Connolly TM; Tang C; Ballard JE; Kuo Y; Adarayan ED; Prueksaritanont T; Zrada MM; Marino MJ; Graufelds VK; DiLella AG; Reynolds IJ; Vargas HM; Bunting PB; Woltmann RF; Magee MM; Koblan KS; Renger JJ
J Med Chem; 2008 Oct; 51(20):6471-7. PubMed ID: 18817368
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of 1,3-dioxoisoindoline-5-carboxamide derivatives as T-type calcium channel blockers.
Kim HS; Kim Y; Doddareddy MR; Seo SH; Rhim H; Tae J; Pae AN; Choo H; Cho YS
Bioorg Med Chem Lett; 2007 Jan; 17(2):476-81. PubMed ID: 17092715
[TBL] [Abstract][Full Text] [Related]
17. Pyridyl amides as potent inhibitors of T-type calcium channels.
Reger TS; Yang ZQ; Schlegel KA; Shu Y; Mattern C; Cube R; Rittle KE; McGaughey GB; Hartman GD; Tang C; Ballard J; Kuo Y; Prueksaritanont T; Nuss CE; Doran SM; Fox SV; Garson SL; Li Y; Kraus RL; Uebele VN; Renger JJ; Barrow JC
Bioorg Med Chem Lett; 2011 Mar; 21(6):1692-6. PubMed ID: 21316226
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of novel T-type Ca2+ channel blockers.
Jung HK; Doddareddy MR; Cha JH; Rhim H; Cho YS; Koh HY; Jung BY; Pae AN
Bioorg Med Chem; 2004 Aug; 12(15):3965-70. PubMed ID: 15246072
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, evaluation of pharmacological activities and quantitative structure-activity relationship studies of a novel group of bis(4-nitroaryl-1,4-dihyropyridine).
Miri R; Javidnia K; Hemmateenejad B; Tabarzad M; Jafarpour M
Chem Biol Drug Des; 2009 Feb; 73(2):225-35. PubMed ID: 19207425
[TBL] [Abstract][Full Text] [Related]
20. Discovery and evaluation of Ca
Bezençon O; Remeň L; Richard S; Roch C; Kessler M; Ertel EA; Moon R; Mawet J; Pfeifer T; Capeleto B
Bioorg Med Chem Lett; 2017 Dec; 27(23):5326-5331. PubMed ID: 29074257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
